Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates

BMC Immunology

Volumn 17, Issue 1, 2016, Pages

  Rodríguez Álvarez, Yunier ^a   Morera Díaz, Yanelys ^a   Gerónimo Pérez, Haydee ^b   Castro Velazco, Jorge ^b   Martínez Castillo, Rafael ^b   Puente Pérez, Pedro ^b   Besada Pérez, Vladimir ^b   Hardy Rando, Eugenio ^c   Chico Capote, Araceli ^d   Martínez Cordovez, Klaudia ^a   Santos Savio, Alicia ^a  

^a Center of Pharmaceutical Chemistry Cuba   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c UNIVERSITY OF HAVANA   (Cuba)

^d HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

Alum; CTLL 2 cells; Cytokine; IL 15; Immunization; Neutralizing Abs; Non human primates

Indexed keywords

ALUMINUM HYDROXIDE; CD56 ANTIGEN; FREUND ADJUVANT; INTERLEUKIN 15; INTERLEUKIN 2; MONTANIDE ISA 51; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR;

ACTIVE IMMUNIZATION; ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIOCHEMISTRY; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACACA FASCICULARIS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN SECRETION; SYNOVIOCYTE;

EID: 84992035724     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-016-0168-6     Document Type: Article

References (67)

1. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 2003;14(2):123-37.
2. Schmidt-Weber CB. Anti-IL-4 as a new strategy in allergy. Chem Immunol Allergy. 2012;96:120-5.
3. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis. 2013;5(3):141-52.
4. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.
5. Zaragoza JZ, Martínez ER, Avelar MD, Magallanes NG, Pérez NV. Th17 cells in autoimmune and infectious diseases. Int J Inflamm. 2014;2014:651503.
6. Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003;115(5):390-7.
7. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:545493.
8. Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol. 2011;2011:348530.
9. Di Sabatino A, Calarota SA, Vidali F, MacDonald TT, Corazza GR. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev. 2011;22(1):19-33.
10. McInnes IB. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. Ernst Schering Res Found Workshop. 2006;56:29-44.
11. Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Transl Res. 2012;160(5):321-31.
12. Gonzalez-Alvaro I, Ortiz AM, García-Vicuna R, Balsa A, Pascual-Salcedo D, Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol. 2003;21(5):639-42.
13. + T cells. PLoS One. 2012;7(9):e45299.
14. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112(10):1571-80.
15. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G. Targeting interleukin-15 in patients with rheumatoid arthritis. A proof-of-concept study. Arthritis Rheum. 2005;52(9):2686-92.
16. + T cells: a role in the pathogenesis of rheumatoid arthritis? Immunology. 2009;126(1):63-73.
17. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1999;42(7):1508-16.
18. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med. 1997;3(2):189-95.
19. Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol. 2007;37(10):2744-52.
20. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer. 2000;87(1):79-85.
21. Link A, Bachmann MF. Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy. 2010;2(4):561-74.
22. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today. 2004;9(2):72-81.
23. Delavallée L, Assier E, Semerano L, Bessis N, Boissier M. Emerging applications of anticytokine vaccines. Expert Rev Vaccines. 2008;7(10):1507-10.
24. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3(1):81-8.
25. Delavallée L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, et al. Vaccination with cytokines in autoimmune diseases. Ann Med. 2008;40(5):343-51.
26. Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R. TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation. Proc Natl Acad Sci U S A. 2006;103(51):19442-7.
27. Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snich J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol. 2004;34(12):3572-81.
28. Bertin-Maghit SM, Capini CJ, Bessis N, Chomilier J, Muller S, Abbas A, et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modeling. Vaccine. 2005;23(33):4228-35.
29. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36(11):2857-67.
30. Uyttenhove C, Sommereyns C, Théate I, Michiels T, Van Snick J. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci. 2007;1110(1):330-6.
31. Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol. 2008;38(3):877-87.
32. Uyttenhove C, Van Snick J. Anti-cytokine auto-vaccinations as tools for the analysis of cytokine function in vivo. Cytokine Growth Factor Rev. 2012;23(1-2):1-6.
33. Bizzini B, Drouet B, Zagury D, Abitbol M, Burny A, Boissier MC. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy. 2010;2(3):347-65.
34. Santos A, Morera Y, Araña M, Ferrero J, Moro A, García J, et al. Obtaining biologically active IL-15 in Escherichia coli. Biotecnol Apl. 2000;17(4):221-4.
35. Rodríguez Y, Gerónimo H, Garay H, Castro J, García G, Santos A. Application of a colorimetric CTLL-2 cell proliferation assay for the evaluation of IL-15 antagonists. Biotecnol Apl. 2014;31(4):291-6.
36. Mossman T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
37. Pettit DK, Bonnert TP, Eisenmann J, Srinivasan S, Paxton R, Beers C, et al. Structure-Function studies of Interleukin-15 using site specific mutagenesis, polyethylene glycol conjugation, and homology modelling. J Biol Chem. 1997;272(4):2312-8.
38. Santos A, Machado AC, Chico A, Miranda J, Rodríguez Y, Bringas R, et al. Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from Rheumatoid arthritis patients. BMC Musculoskelet Disord. 2015;16:51.
39. Carroll HP, Paunovic V, Gadina M. Crossed signals: the role of Interleukin-15 and Interleukin-18 in autoimmunity. Rheumatology. 2008;47(9):1269-77.
40. Steinway SN, Loughran TP. Targeting IL-15 in large granular lymphocyte leukemia. Expert Rev Clin Immunol. 2013;9(5):405-8.
41. Kroemer A, Xiao X, Degauque N, Edtinger K, Wei H, Demirci G. The innate NK cells, allograft rejection, and a key role for IL-15. J Immunol. 2008;180(12):7818-26.
42. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264(5161):965-8.
43. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine. 2002;20(3):121-9.
44. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70(6):849-60.
45. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008;38(8):2068-71.
46. Mastelic B, Ahmed S, Egan W, Giudice G, Golding H, Gust I, et al. Mode of action of adjuvants: Implications for vaccine safety and design. Biologicals. 2010;38(5):594-601.
47. De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol. 2013;4(214):1-6.
48. Zagury D, Burny A, Gallo RC. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci U S A. 2001;98(14):8024-9.
49. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
50. Waldmann TA. The shared and contrasting roles of IL-2 and IL-15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219-27.
51. Thurkow EW, Van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol. 1997;181(4):444-50.
52. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol. 1997;27(3):624-32.
53. Meazza R, Azzarone B, Orengo AM, Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol. 2011;2011:861920.
54. + T cells. J Immunol. 2008;180(7):4391-401.
55. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9.
56. Poaty-Mavoungou V, Toure FS, Tevi-Benissan C, Mavoungou E. Enhancement of natural killer cell activation and antibody-dependent cellular cytotoxicity by interferon-α and interleukin-12 in vaginal mucosae Sivmac251-infected Macaca fascicularis. Viral Immunol. 2002;15(1):197-212.
57. Webster RL, Johnson RP. Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology. 2005;115(2):206-14.
58. Carville A, Evans IT, Reeves KR. Characterization of circulating natural killer cells in neotropical primates. PLoS One. 2013;8(11):e78793.
59. Hong SH, Rajakumar AP, Billingsley MJ, Reeves KR, Johnson PR. No monkey business: why studying NK cells in non-human primates pays off. Front Immunol. 2013;4:32.
60. Mavilio D, Benjamin J, Kim D, Lombardo G, Daucher M, Kinter A, et al. Identification of NKG2A and NKp80 as specific natural killer cell markers in Rhesus and pigtailed monkeys. Blood. 2005;106(5):1718-25.
61. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with Epidermal Growth Factor (EGF) in advanced lung cancer. Hum Vaccin. 2007;3(1):e1-6.
62. Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Pérez PP, Alba JS, et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine. 2010;28(19):3453-61.
63. Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T. Therapeutic vaccination with TNF-kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized. Controlled clinical trial. PLoS One. 2014;9(12):e113465.
64. Meazza R, Verdiani S, Biassoni R, Coppolecchia M, Gaggero A, Orengo AM, et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene. 1996;12(10):2187-92.
65. Lamana A, Ortiz AM, Alvaro-Gracia JM, Díaz-Sánchez B, Novalbos J, García-Vicuña R, et al. Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw. 2010;21(3):186-94.
66. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009;114:2417-26.
67. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med. 2003;17(3):273-81.